PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: MARKET SEGMENTATION BY PRODUCT • Market segmentation by product • Comparison by product • Acquired lymphopenia - Market size and forecast 2018-2023 • Inherited lymphopenia - Market size and forecast 2018-2023 • Market opportunity by product PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 09: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 10: MARKET TRENDS • Increasing research in regenerative medicines • Strategic alliances • Presence of patient assistance programs PART 11: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 12: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • AbbVie Inc. • Bristol-Myers Squibb Co. • CSL Ltd. • Gilead Sciences Inc. • GlaxoSmithKline Plc • Grifols SA • Johnson & Johnson Services Inc. • Merck & Co. Inc. • Novartis AG • Sanofi PART 13: APPENDIX • Research methodology • List of abbreviations • Definition of market positioning of vendors   Exhibit 01: Years in consideration Exhibit 02: Exhibit 03: Global pharmaceuticals market Exhibit 04: Segments of global pharmaceuticals market Exhibit 05: Market characteristics Exhibit 06: Market characteristics analysis Exhibit 07: Market segments Exhibit 08: Market definition - Inclusions and exclusions checklist Exhibit 09: Market size 2018 Exhibit 10: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 11: Global market: Year-over-year growth 2019-2023 (%) Exhibit 12: Five forces analysis 2018 Exhibit 13: Five forces analysis 2023 Exhibit 14: Bargaining power of buyers Exhibit 15: Bargaining power of suppliers Exhibit 16: Threat of new entrants Exhibit 17: Threat of substitutes Exhibit 18: Threat of rivalry Exhibit 19: Market condition - Five forces 2018 Exhibit 20: Product - Market share 2018-2023 (%) Exhibit 21: Comparison by product Exhibit 22: Acquired lymphopenia - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Acquired lymphopenia - Year-over-year growth 2019-2023 (%) Exhibit 24: Inherited lymphopenia - Market size and forecast 2018-2023 ($ millions) Exhibit 25: Inherited lymphopenia - Year-over-year growth 2019-2023 (%) Exhibit 26: Market opportunity by product Exhibit 27: Customer landscape Exhibit 28: Customer landscape analysis Exhibit 29: Market share by geography 2018-2023 (%) Exhibit 30: Geographic comparison Exhibit 31: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 32: North America - Year-over-year growth 2019-2023 (%) Exhibit 33: Top 3 countries in North America Exhibit 34: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 35: Europe - Year-over-year growth 2019-2023 (%) Exhibit 36: Top 3 countries in Europe Exhibit 37: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 38: Asia - Year-over-year growth 2019-2023 (%) Exhibit 39: Top 3 countries in Asia Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 41: ROW - Year-over-year growth 2019-2023 (%) Exhibit 42: Top 3 countries in ROW Exhibit 43: Key leading countries Exhibit 44: Market opportunity Exhibit 45: Decision framework Exhibit 46: Impact of drivers and challenges Exhibit 47: Vendor landscape Exhibit 48: Landscape disruption Exhibit 49: Vendor landscape analysis Exhibit 50: Vendors covered Exhibit 51: Vendor classification Exhibit 52: Market positioning of vendors Exhibit 53: AbbVie Inc. - Vendor overview Exhibit 54: AbbVie Inc. - Business segments Exhibit 55: AbbVie Inc. - Organizational developments Exhibit 56: AbbVie Inc. - Geographic focus Exhibit 57: AbbVie Inc. - Key offerings Exhibit 58: AbbVie Inc. - Key customers Exhibit 59: Bristol-Myers Squibb Co. - Vendor overview Exhibit 60: Bristol-Myers Squibb Co. - Business segments Exhibit 61: Bristol-Myers Squibb Co. - Organizational developments Exhibit 62: Bristol-Myers Squibb Co. - Geographic focus Exhibit 63: Bristol-Myers Squibb Co. - Key offerings Exhibit 64: Bristol-Myers Squibb Co. - Key customers Exhibit 65: CSL Ltd. - Vendor overview Exhibit 66: CSL Ltd. - Business segments Exhibit 67: CSL Ltd. - Organizational developments Exhibit 68: CSL Ltd. - Geographic focus Exhibit 69: CSL Ltd. - Segment focus Exhibit 70: CSL Ltd. - Key offerings Exhibit 71: CSL Ltd. - Key customers Exhibit 72: Gilead Sciences Inc. - Vendor overview Exhibit 73: Gilead Sciences Inc. - Business segments Exhibit 74: Gilead Sciences Inc. - Organizational developments Exhibit 75: Gilead Sciences Inc. - Geographic focus Exhibit 76: Gilead Sciences Inc. - Key offerings Exhibit 77: Gilead Sciences Inc. - Key customers Exhibit 78: GlaxoSmithKline Plc - Vendor overview Exhibit 79: GlaxoSmithKline Plc - Business segments Exhibit 80: GlaxoSmithKline Plc - Organizational developments Exhibit 81: GlaxoSmithKline Plc - Geographic focus Exhibit 82: GlaxoSmithKline Plc - Segment focus Exhibit 83: GlaxoSmithKline Plc - Key offerings Exhibit 84: GlaxoSmithKline Plc - Key customers Exhibit 85: Grifols SA - Vendor overview7 Exhibit 86: Grifols SA - Business segments7 Exhibit 87: Grifols SA - Organizational developments Exhibit 88: Grifols SA - Geographic focus Exhibit 89: Grifols SA - Segment focus Exhibit 90: Grifols SA - Key offerings Exhibit 91: Grifols SA - Key customers Exhibit 92: Johnson & Johnson Services Inc. - Vendor overview Exhibit 93: Johnson & Johnson Services Inc. - Business segments Exhibit 94: Johnson & Johnson Services Inc. - Organizational developments Exhibit 95: Johnson & Johnson Services Inc. - Geographic focus Exhibit 96: Johnson & Johnson Services Inc. - Segment focus Exhibit 97: Johnson & Johnson Services Inc. - Key offerings Exhibit 98: Johnson & Johnson Services Inc. - Key customers Exhibit 99: Merck & Co. Inc. - Vendor overview Exhibit 100: Merck & Co. Inc. - Business segments Exhibit 101: Merck & Co. Inc. - Organizational developments Exhibit 102: Merck & Co. Inc. - Geographic focus Exhibit 103: Merck & Co. Inc. - Segment focus Exhibit 104: Merck & Co. Inc. - Key offerings Exhibit 105: Merck & Co. Inc. - Key customers Exhibit 106: Novartis AG - Vendor overview Exhibit 107: Novartis AG - Business segments Exhibit 108: Novartis AG - Organizational developments Exhibit 109: Novartis AG - Geographic focus Exhibit 110: Novartis AG - Segment focus Exhibit 111: Novartis AG - Key offerings Exhibit 112: Novartis AG - Key customers Exhibit 113: Sanofi - Vendor overview Exhibit 114: Sanofi - Business segments Exhibit 115: Sanofi - Organizational developments Exhibit 116: Sanofi - Geographic focus Exhibit 117: Sanofi - Segment focus Exhibit 118: Sanofi - Key offerings Exhibit 119: Sanofi - Key customers Exhibit 120: Validation techniques employed for market sizing Exhibit 121: List of abbreviations Exhibit 122: Definition of market positioning of vendors

AbbVie Inc., Bristol-Myers Squibb Co., CSL Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Grifols SA, Johnson & Johnson Services Inc., Merck & Co. Inc., Novartis AG, and Sanofi.